[New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement]

Bull Cancer. 2021 May;108(5):446-447. doi: 10.1016/j.bulcan.2021.03.007. Epub 2021 Apr 27.
[Article in French]
No abstract available

Keywords: Cholangiocarcinoma; Cholangiocarcinomes; FGFR2; Fusion transcripts; Transcrits de fusion.

Publication types

  • Letter

MeSH terms

  • Bile Duct Neoplasms / drug therapy*
  • Bile Duct Neoplasms / genetics*
  • Cholangiocarcinoma / drug therapy*
  • Cholangiocarcinoma / genetics*
  • Clinical Trials, Phase II as Topic
  • Drug Approval
  • Europe
  • Gene Rearrangement
  • Humans
  • Morpholines / therapeutic use*
  • Multicenter Studies as Topic
  • Oncogene Proteins, Fusion
  • Pyrimidines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Receptor, Fibroblast Growth Factor, Type 2 / antagonists & inhibitors
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics*

Substances

  • Morpholines
  • Oncogene Proteins, Fusion
  • Pyrimidines
  • Pyrroles
  • FGFR2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2
  • pemigatinib